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Background: Whole of population studies reporting long-term outcomes following radical prostatec-
tomy (RP) are scarce. We aimed to evaluate the long-term outcomes in men with prostate cancer (PC)
treated with RP in a whole of population cohort. A secondary objective was to evaluate the inﬂuence of
mode of presentation on PC speciﬁc mortality (PCSM).
Methods: A prospective database of all cases of RP performed in Victoria, Australia between 1995 and
2000 was established within the Victorian Cancer Registry. Specimen histopathology reports and
prostate-speciﬁc antigen (PSA) values were obtained by record linkage to pathology laboratories. Mode
of presentation was recorded as either PSA screened (PSA testing offered in absence of voiding symp-
toms) or symptomatic (diagnosis of PC following presentation with voiding symptoms). Multivariate Cox
and competing risk regression models were ﬁtted to analyze all-cause mortality, biochemical recurrence,
and PCSM.
Results: Between 1995 and 2000, 2,154 men underwent RP in Victoria. During median follow up of 10.2
years (range 0.26e13.5 years), 74 men died from PC. In addition to Gleason score and pathological stage,
symptomatic presentation was associated with PCSM. After adjusting for stage and PSA, no difference in
PCSM was found between men with Gleason score  6 and Gleason score 3 þ 4 ¼ 7. Men with Gleason
score 4þ 3 had signiﬁcantly greater cumulative incidence of PCSM compared with men with Gleason
score 3þ 4.
Conclusions: Primary Gleason pattern in Gleason 7 PC is an important prognosticator of survival. Our
ﬁndings suggest that concomitant voiding symptoms should be considered in the work-up and treat-
ment of PC.
Copyright © 2015 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Prostate cancer (PC) is the most commonly diagnosed male
malignancy and the second most common cause of cancer-related
death in Australia, and its incidence continues to increase in the
Asia-Paciﬁc region.1,2 The use of open radical prostatectomy (RP) foreidelberg Vic, 3084, Australia.
wrentschuk), damienbolton@
ciﬁc Prostate Society, Published bthe surgical management of localized PC increased dramatically
during the 1990s subsequent to the increasing use of prostate-
speciﬁc antigen (PSA) testing and improved operative
techniques.3e5 In more recent years, advances in laparoscopic and
robotic surgery have seen a signiﬁcant fall in rates of open surgery
for PC.6 Due to the relatively recent uptake of robotic surgery, long-
term survival data following surgery for PC is largely limited to
open RP series.
PC is associated with a long natural history. Multiple studies of
long-term follow-up data in patients managed with observation
and surgery have been published, although few of these representy Elsevier. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Baseline characteristics.
Median (mean) Range
Age at surgery (yr) 61.9 (61.4) 38.9e81.7
PSA (ng/mL) 8.4 (10.2) 0e112
Gleason grade n %
2e6 1,123 58.1
7 (3þ 4) 489 25.3
7 (4þ 3) 185 9.6
8e10 135 7.0
Pathological stage n %
T1/T2 1,437 74.4
T3a 294 15.2
T3b 160 8.3
T4 41 2.1
Mode of presentation n %
Symptomatic 631 32.7
Nonsymptomatic 1,301 67.3
Urologist (206) (15.8)
GP screen (1,095) (84.2)
GP, general practitioner; PSA, prostate-speciﬁc antigen.
Prostate Int 3 (2015) 75e7976whole of population series.7e13 Lower PC speciﬁc mortality (PCSM)
observed in men with more low-risk disease has resulted in a shift
towards increased use of active surveillance.14e16 Conversely, men
with higher risk PC may have the greatest survival beneﬁt from
surgery, as those with aggressive disease may be cured by RP alone
or as part of multimodality treatment.9,17,18
Presentation in menwith PC is usually asymptomatic and based
on serum PSA, however, there is a subgroup of men presenting with
lower urinary tract symptoms (LUTS) who potentially harbor a
malignancy.19,20
In this study, we evaluate the long-term survival outcomes in a
prospective whole of population study of men treated with RP in
the PSA era. Furthermore, we sought to identify the impact on
PCSM of symptomatic presentation with voiding dysfunction
leading to cancer diagnosis, as opposed to diagnosis based purely
on PSA testing.
Materials and methods
Patient population
The Victorian Radical Prostatectomy Registry is a prospective
whole of population series of men who underwent RP for the
treatment of clinically localized prostate adenocarcinoma between
1995 and 2000 in Victoria, Australia. This database was established
within the Victorian Cancer Registry, which documents all cancer
cases in the state, excluding nonmelanoma skin cancer, and is
managed by the Cancer Council Victoria. Further details regarding
patient registration and data collection have previously been
published.3
Clinical and histopathological details
The mode of presentation was recorded at registration as either
PSA screened (PSA testing offered by a urologist or general practi-
tioner in the absence of signiﬁcant voiding symptoms), symptom-
atic, or other. Symptomatic presentation was deﬁned as patients
who sought treatment for irritative or obstructive symptoms and
were subsequently diagnosed with PC. Specimen histopathology
reports, and pre- and post-RP PSA surveillance values were ob-
tained by record linkage to pathology laboratories. Biochemical
recurrence (BCR) post-RP was deﬁned as two consecutive PSA
values  0.2 ng/mL and the latter date taken as the time of recur-
rence. Deaths were recorded by the Victorian Cancer Registry as
either death from PC, death from another cancer, or death from
another cause. Men who received neoadjuvant therapy were
excluded from all analyses.
Statistical analysis
Multivariate Cox proportional hazards models were ﬁtted to
analyze all-cause mortality and time to BCR. Competing risks
regression based on the Fine and Gray model, with other cause
mortality as the competing risk, was ﬁtted to analyze overall PCSM
as well as subgroup PCSM and was used to generate cumulative
incidence plots. In all regressions, time from surgery was used as
the time axis and all covariates were entered into the model
simultaneously. Formal statistical testing of the proportional haz-
ards assumption in the Cox models using Schoenfeld residuals
found that it was not violated. Proportionality was assessed in the
competing risks regression by including interactions with a time
variable for all covariates and these were found to be nonsigniﬁ-
cant. In the symptomatic subgroup analysis, age at surgery and PSA
were found to be not normally distributed by the skewness-
kurtosis test and hence were compared with the Wilcoxon ranksum test. Grade and stage were compared using the Kruskal-Wallis
test. All tests were two sided and signiﬁcance level was set at
P 0.05.
Analyses were performed using Stata 12.1 SE (Statacorp, College
Station, TX, USA).
Results
The full registry comprises 2,154 patients. Baseline characteris-
tics are shown in Table 1. A total of 2,112 individuals had follow-up
data available (98.1%). After excluding men who received neo-
adjuvant therapy, 1,935 individuals had data available including
grade, stage, and PSA. These men constitute the population set
analyzed in this report. During a median follow up of 10.2 years
(range 0.26e13.5 years), 622 men experienced BCR and 233 men
died, including 74 from PC.
Results of the multivariate Cox regression analysis used to
model risk of BCR, all-cause mortality, and PCSM are shown in
Table 2. Increasing Gleason grade and tumor stage were strongly
associated with time to BCR and PCSM. The nonsigniﬁcant result for
pT4 tumors in all-cause mortality was likely due to the small
number of events in this series. A higher baseline PSA was associ-
ated with reduced time to BCR, but was not found to be predictive
of PCSM or overall mortality. Older age at surgery predicted time to
all-cause mortality but not PCSM.
Symptomatic presentation with subsequent diagnosis of PC was
signiﬁcantly associated with older age and higher PSA, grade, and
stage as shown in Table 3. After multivariate adjustment of these
clinicopathologic parameters, there was still an association be-
tween symptomatic presentation and time to PCSM (P¼ 0.036,
Fig. 1).
There were 16 PC-speciﬁc deaths observed in men who had
Gleason score  6 disease and 14 in men with Gleason score
3 þ 4 ¼ 7 disease. After adjusting for pathological stage, PCSM
outcomes for Gleason score  6 and 3þ 4 tumors did not signiﬁ-
cantly differ (P¼ 0.231, Fig. 2). In a low risk subgroup of men with
PSA 10 ng/mL and pT1/T2 stage (n¼ 994, 51.4%), 17 PC deaths
were observed overall, including 11 and four men with Gleason
score 6 and 3þ 4, respectively. Similarly, no signiﬁcant difference
in PCSM was observed between the two groups (P¼ 0.649),
although the number of events was small (Fig. 3).
In the subgroup of men with Gleason 7 tumors (n¼ 674), 35
deaths were observed, including 14 and 21 in men with Gleason
Table 2
Multivariate cox regression analysis.
Biochemical recurrence All-cause mortality Prostate cancer-speciﬁc mortality
n HR (95% CI) P n HR (95% CI) P n HR (95% CI) P
Baseline characteristics
Symptomatic (vs. not) 215 1.06 (0.90e1.25) 0.481 101 1.34 (1.03e1.74) 0.029 37 1.64 (1.04e2.60) 0.034
Age (yr) e 1.00 (0.99e1.01) 0.997 e 1.07 (1.04e1.09) < 0.001 e 0.99 (0.95e1.03) 0.514
PSA (per 5 ng/mL) e 1.09 (1.05e1.12) < 0.001 e 1.01 (0.94e1.07) 0.862 e 1.00 (0.90e1.10) 0.950
Gleason score
 6 (reference group) 245 e e 104 e e 16 e e
7 (3þ 4) 203 1.90 (1.57e2.30) < 0.001 52 1.08 (0.77e1.52) 0.665 14 1.61 (0.79e3.30) 0.194
7 (4þ 3) 96 2.34 (1.83e3.01) < 0.001 37 1.72 (1.15e2.58) 0.008 21 4.75 (2.45e9.22) < 0.001
8e10 78 2.24 (1.69e2.98) < 0.001 40 2.36 (1.55e3.60) < 0.001 23 5.39 (2.61e11.11) < 0.001
Pathological stage
T1/T2 (reference group) 369 e e 139 e e 23 e e
T3a 123 1.35 (1.09e1.67) 0.006 38 1.15 (0.79e1.66) 0.478 16 2.37 (1.23e4.55) 0.010
T3b 107 2.36 (1.86e2.98) < 0.001 49 2.25 (1.54e3.30) < 0.001 31 5.83 (3.18e10.69) < 0.001
T4 23 2.03 (1.29e3.19) 0.002 7 1.58 (0.73e3.42) 0.245 4 5.15 (1.88e14.06) 0.001
CI, conﬁdence interval, HR, hazard ratio; PSA, prostate-speciﬁc antigen; SHR, subhazard ratio.
Table 3
Comparison of symptomatic versus nonsymptomatic men.
Symptomatic Median (mean) Nonsymptomatic Median (mean) P (for difference)
Age (yr), median (mean) 62.78 (62.09) 61.66 (61.06) < 0.001
PSA (ng/mL), median (mean) 7.9 (10.36) 8.2 (10.19) 0.017
Gleason Score
 6 (reference group) 374 (59.3) 749 (57.6) 0.038
7 (3þ 4) 138 (21.9) 351 (27.0) e
7 (4þ 3) 65 (10.3) 120 (9.2) e
8e10 54 (8.6%) 81 (6.2) e
Pathological stage
T1/T2 (reference group) 455 (72.1) 982 (75.5) 0.023
T3a 91 (14.4) 203 (15.6) e
T3b 68 (10.8) 92 (7.1) e
T4 17 (2.7) 24 (1.8) e
Data are presented as n (%) unless otherwise indicated.
PSA, prostate-speciﬁc antigen.
Ta et al / Prostate cancer mortality 77score 3þ 4 and 4þ 3 disease, respectively. Men with Gleason 7
disease and primary pattern 4 had signiﬁcantly greater cumulative
incidence of PCSM compared with menwith Gleason 7 disease and
primary pattern 3, as shown in Fig. 4 (subhazard ratio¼ 2.79, 95%
conﬁdence interval 1.40e5.54, P¼ 0.003).
Discussion
This study represents the largest reported whole of population
cohort of men treated with RP with >10-years follow up. AlthoughProstate cancer specific mortalitya)
by symptomatic presentation
SHR = 1.64 (1.04-2.60)
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Fig. 1. Symptomatic presentation and prostate cancer-speciﬁc mortality. a) After
adjustment for age, PSA, grade and stage. PSA, prostate-speciﬁc antigen; SHR, sub-
hazard ratio.evaluating the role of screening was not a primary endpoint in this
study, we found that in addition to previously demonstrated
pathologic predictors of PCSM, mode of presentation inﬂuenced
survival outcomes. We report a difference in survival between men
who were diagnosed with PC following PSA testing offered by their
family doctor or urologist, compared with men who had diagnosis
of PC made following a presentation with symptoms of urinary
obstruction.
Symptomatic presentation was associated with older age and
higher PSA, grade, and stage, however, even after adjustment for0 5 10 15
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Prostate cancer specific mortalitya)
Gleason less than 7 vs. 7(3+4)
SHR = 1.54 (0.76-3.10)
P = 0.231
Gleason less than 7 Gleason 7 (3+4)
Fig. 2. Comparison of Gleason score  6 and 7 (3 þ 4). a) After adjustment for stage.
SHR, subhazard ratio.
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Prostate cancer specific mortality
Gleason less than 7 vs. 7(3+4) in low risk tumours
SHR = 1.30 (0.42-4.02)
P = 0.649
Fig. 3. Prostate cancer speciﬁc mortality (PCSM) in lower risk prostate cancer (Gleason
score  3 þ 4, PSA  10, pT1/2). PSA, prostate-speciﬁc antigen; SHR, subhazard ratio.
Prostate Int 3 (2015) 75e7978these parameters, there was an association between symptomatic
presentation and reduced time to PCSM.Minimal data studying this
parameter has been published to date, possibly because this vari-
able is less commonly noted now that most PC is PSA detected in
North America and Europe. Data from The Swedish National Pros-
tate Cancer Register has shown that most men with PC diagnosed
after a health check-up, compared with men presenting with LUTS,
have localized tumors of low or intermediate risk.20 Lee et al19
found that men with preoperative LUTS as demonstrated by In-
ternational Prostate Symptoms Score > 8 had a higher incidence of
pathologic pT3a disease at the time of RP compared with menwith
no LUTS.
A possible explanation for this ﬁnding may be prostate volume,
as men with larger prostates are more likely to experience LUTS.
However, data regarding prostate volume was not available for all
patients in our study. Although a relationship between prostate
volume and symptomatic presentationmay exist based on our data,
other factors may exist, such as PC arising from the transition zone.
This requires further study. Nonetheless, our data suggest that men
who present with voiding symptoms should be counseled about
PSA testing as part of their work-up of BPH, as some of these men
may harbor more aggressive PC.
A further notable ﬁnding was the good prognosis of the sub-
group of men with Gleason score 3þ 4 PC, especially those withProstate cancer specific mortalitya)
Gleason 7(3+4) vs. 7(4+3)
SHR = 2.79 (1.40-5.54)
P = 0.003
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Fig. 4. Effect of primary pattern on prostate cancer speciﬁc mortality (PCSM) in
Gleason 7 prostate cancer. a) After adjustment for stage. SHR, subhazard ratio.low-risk features such as PSA 10 ng/mL and organ-conﬁned dis-
ease. Thesemen had no increased risk of PCSM comparedwithmen
with Gleason score 6. This suggests that in low-volume PC treated
with RP, secondary Gleason pattern 4 confers little increased risk of
mortality.
Part of this lack of variance in outcomes between Gleason score
 6 and Gleason score 3þ 4 PC in this series where all men were
treated by RP may be that although the number of PC-related
deaths in both groups was small, the crude mortality rate from
Gleason score  6 disease was higher than expected. In the sub-
group of men with Gleason score  6, PSA 10 ng/mL, and organ-
conﬁned disease, 11 deaths from PC were observed. This observa-
tion may be partly explained by the multicenter study design
whereby deaths were coded by a centralized cancer registry based
on information from death certiﬁcates rather than medical records,
and it is possible, but unlikely, that a greater proportion of deaths
may have been overattributed to PC. Furthermore, prior to the
modiﬁcation of the Gleason scoring system by the International
Society of Urological Pathology in 2005, it is possible that some of
the Gleason  6 tumors may have represented Gleason 7
tumors.21,22
We found that the subgroup of men with Gleason 7 PC had
heterogeneous outcomes. It has been previously shown that pri-
mary Gleason pattern 4 inmenwith Gleason 7 PC is associatedwith
greater BCR following surgery compared with primary Gleason
score 3.23e26 However, the effect of primary Gleason pattern 4 on
mortality outcomes in these men is less clear. Among men with
Gleason 3þ 4 and 4þ 3 PC, Eggener et al10 found no difference in
15-year PCSM in >20,000 men treated with RP at multiple large US
institutions. Conversely, Wright et al27 demonstrated higher rates
of BCR and PCSM in men with Gleason score 4þ 3 compared with
men with Gleason score 3þ 4 in a population-based cohort of men
with Gleason 7 PC and median 13-year follow up, although the
study was limited to 753men from a single county under the age of
65 years. Stark et al28 similarly demonstrated a threefold increase in
PCSM in men with Gleason score 4þ 3 compared with men with
Gleason score 3þ 4 with 20-year follow up, however, the analysis
did not control for PSA or tumor stage. Furthermore, the study was
limited to 693 RP specimens and all men were identiﬁed from
health survey studies conducted on health professionals.
This heterogeneity in outcomes in menwith Gleason 7 PC in our
study may further be explained by tumor volume. A trend between
increasing tumor volume and adverse pathological ﬁndings at RP
was noted, but was not reported, as tumor volume was not avail-
able for all men. It is possible that the presence of primary Gleason
pattern 4 is associated with increased tumor volume, and this re-
quires further evaluation. Nonetheless, the distinctions between
the predominant Gleason patterns remain important. We conﬁrm
in a whole of population setting that amongst men with Gleason 7
PC treated with RP, primary Gleason pattern 4 confers signiﬁcantly
greater PCSM compared with primary Gleason pattern 3.
Some limitations of this study include potentially incomplete
data regarding adjuvant or salvage radiation therapy, and an
inability to comment on functional or quality of life measures,
which are important outcomes following RP. Prostate volume and
tumor volume data were also not available for all men. However,
this prospective study represents a statewide whole of population
register of RP performed by all urologists of varying experience in
large tertiary and smaller community hospitals. By including men
of varying pathology, socioeconomic status, and residency, and all
urologists undertaking RP regardless of their experience or sur-
gical volume, this study is representative of long-term outcomes
on a population and community level that may not be reﬂected
in large series from high-volume institutions from the US and
Europe.
Ta et al / Prostate cancer mortality 79Conclusion
In this whole of population based study, there appears to be
increased PCSM for men treated by RP for clinically localized dis-
ease where their presentation was with symptomatic voiding dif-
ﬁculty, in comparisonwith menwho had their cancer diagnosed on
the basis of PSA elevation alone. This ﬁnding should be considered
in determining the most appropriate form of treatment for indi-
vidual patients, including where active surveillance may be an
option. Furthermore, Gleason score 3þ 4¼ 7 PC has been shown in
this whole-of-population series to have signiﬁcantly less PCSM
than Gleason score 4 þ 3 ¼ 7 disease, and similar to that of Gleason
score 6 disease, reinforcing the signiﬁcance of this pathologic
distinction.
Conﬂicts of interest
All contributing authors declare no conﬂicts of interest
Acknowledgments
We want to thank participating urologists for their valuable
contribution to the Victorian Radical Prostatectomy Registry. Initial
funding for this project was obtained from a grant in aid from Esso
Australia. Ongoing support and infrastructure has been provided by
The Cancer Council of Victoria and by the Whitten Foundation
References
1. Baade PD, Youlden DR, Cramb SM, Dunn J, Gardiner RA. Epidemiology of
prostate cancer in the Asia-Paciﬁc region. Prostate Int 2013;1:47e58.
2. Thursﬁeld V, Farrugia H, Robertson P, Giles G. Cancer in Victoria: statistics and
trends 2013 [Internet]. 2014 [cited 2014 Feb]. Available from: http://www.
cancervic.org.au/downloads/cec/cancer-in-vic/CCV-statistics-trends-2013.pdf.
3. Bolton D, Severi G, Millar JL, Kelsall H, Davidson A-J, Smith C, et al. A whole of
population-based series of radical prostatectomy in Victoria, 1995 to 2000.
Aust N Z J Public Health 2009;33:527e33.
4. Catalona WJ, Carvalhal GF, Mager DE, Smith DS. Potency, continence and
complication rates in 1,870 consecutive radical retropubic prostatectomies.
J Urol 1999;162:433e8.
5. Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into
etiology and prevention. 1982. J Urol 2002;167(2 Pt 2):1005e10.
6. Lowrance WT, Eastham JA, Savage C, Maschino AC, Laudone VP, Dechet CB,
et al. Contemporary open and robotic radical prostatectomy practice patterns
among urologists in the United States. J Urol 2012;187:2087e92.
7. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative
management of clinically localized prostate cancer. JAMA 2005;293:2095e101.
8. Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A,
et al. Natural history of early, localized prostate cancer. JAMA 2004;291:
2713e9.
9. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, et al. Radical
prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med
2011;364:1708e17.10. Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, et al. Predicting
15-year prostate cancer speciﬁc mortality after radical prostatectomy. J Urol
2011;185:869e75.
11. Isbarn H, Wanner M, Salomon G, Steuber T, Schlomm T, Kollermann J, et al.
Long-term data on the survival of patients with prostate cancer treated with
radical prostatectomy in the prostate-speciﬁc antigen era. BJU Int 2010;106:
37e43.
12. Porter CR, Kodama K, Gibbons RP, Correa Jr R, Chun FKH, Perrotte P, et al. 25-
year prostate cancer control and survival outcomes: a 40-year radical prosta-
tectomy single institution series. J Urol 2006;176:569e74.
13. Roehl KA, Han M, Ramos CG, Antenor JAV, Catalona WJ. Cancer progression and
survival rates following anatomical radical retropubic prostatectomy in 3,478
consecutive patients: long-term results. J Urol 2004;172:910e4.
14. Godtman RA, Holmberg E, Khatami A, Stranne J, Hugosson J. Outcome
following active surveillance of men with screen-detected prostate cancer.
Results from the Goteborg randomised population-based prostate cancer
screening trial. Eur Urol 2013;63:101e7.
15. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-
term follow-up of a large, active surveillance cohort with localized prostate
cancer. J Clin Oncol 2010;28:126e31.
16. Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J, et al.
Outcomes in localized prostate cancer: National Prostate Cancer Register of
Sweden follow-up study. J Natl Cancer Inst 2010;102:950e8.
17. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical
prostatectomy versus observation for localized prostate cancer. N Engl J Med
2012;367:203e13.
18. Chung BH. The role of radical prostatectomy in high-risk prostate cancer.
Prostate Int 2013;1:95e101.
19. Lee DH, Lee SH, Lee DH, Chung MS, Chung BH. Are men who undergo radical
prostatectomy with lower urinary tract symptoms at an increased risk for
aggressive prostate cancer? Korean J Urol 2011;52:819e23.
20. Bratt O, Berglund A, Adolfsson J, Johansson J-E, Tornblom M, Stattin P, et al.
Prostate cancer diagnosed after prostate-speciﬁc antigen testing of men
without clinical signs of the disease: a population-based study from the Na-
tional Prostate Cancer Register of Sweden. Scand J Urol Nephrol 2010;44:
384e90.
21. Lavery HJ, Droller MJ. Do Gleason patterns 3 and 4 prostate cancer represent
separate disease states? J Urol 2012;188:1667e75.
22. Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI. Do ade-
nocarcinomas of the prostate with Gleason score (GS) <¼6 have the potential
to metastasize to lymph nodes? Am J Surg Pathol 2012;36:1346e52.
23. Alenda O, Ploussard G, Mouracade P, Xylinas E, de la Taille A, Allory Y, et al.
Impact of the primary Gleason pattern on biochemical recurrence-free survival
after radical prostatectomy: a single-center cohort of 1,248 patients with
Gleason 7 tumors. World J Urol 2011;29:671e6.
24. Chan TY, Partin AW, Walsh PC, Epstein JI. Prognostic signiﬁcance of Gleason
score 3þ4 versus Gleason score 4þ3 tumor at radical prostatectomy. Urology
2000;56:823e7.
25. Khoddami SM, Shariat SF, Lotan Y, Saboorian H, McConnell JD, Sagalowsky AI,
et al. Predictive value of primary Gleason pattern 4 in patients with Gleason
score 7 tumours treated with radical prostatectomy. BJU Int 2004;94:42e6.
26. Ro YK, Lee S, Jeong CW, Hong SK, Byun SS, Lee SE. Biochemical recurrence in
Gleason score 7 prostate cancer in Korean men: signiﬁcance of the primary
Gleason grade. Korean J Urol 2012;53:826e9.
27. Wright JL, Salinas CA, Lin DW, Kolb S, Koopmeiners J, Feng Z, et al. Prostate
cancer speciﬁc mortality and Gleason 7 disease differences in prostate cancer
outcomes between cases with Gleason 4 þ 3 and Gleason 3 þ 4 tumors in a
population based cohort. J Urol 2009;182:2702e7.
28. Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, et al. Gleason
score and lethal prostate cancer: does 3 þ 4 ¼ 4 þ 3? J Clin Oncol 2009;27:
3459e64.
